STEAP2 CAR-T Cells Targeting Prostate Cancer Stem Cells
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for castrate-resistant prostate cancer (CRPC) with metastatic disease, such as chemotherapy with docetaxel, are not curative due to their inability to effectively target slow-cycling cancer cells, including cancer stem cells.
Innovation Solution
The use of chimeric antigen receptor (CAR)-expressing T cells directed against human STEAP2, in combination with androgen receptor antagonists, to specifically target and inhibit the growth of tumor cells in prostate cancer.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If chemotherapy with docetaxel is used to treat castrate-resistant prostate cancer, then survival is prolonged, but the treatment is not curative because it cannot effectively target slow-cycling cancer cells including cancer stem cells
Solution Approach 1:
The patent changes the mechanism of action parameter from microtubule stabilization (docetaxel) to antigen-specific T cell killing (CAR-T). The CAR-T cells are engineered to recognize STEAP2 antigen on prostate cancer cells, enabling them to effectively kill both rapidly proliferating and slow-cycling cancer cells including cancer stem cells, thereby achieving curative effectiveness while maintaining survival prolongation
Solution Approach 2:
The patent combines CAR-T cells with androgen receptor antagonists to create a composite treatment approach. This combination therapy targets cancer cells through multiple mechanisms: CAR-T cells provide antigen-specific cytotoxicity against STEAP2-expressing cells, while androgen receptor antagonists block androgen signaling pathways, together achieving curative effectiveness by eliminating both dividing and quiescent cancer cells
2Productivity
If docetaxel is used to kill rapidly proliferating cells, then tumor burden is reduced, but slow-cycling cancer cells are spared
Solution Approach 1:
The CAR-T cells are engineered with universal STEAP2 targeting capability that enables them to recognize and kill all prostate cancer cells expressing the STEAP2 antigen, regardless of their proliferation status. This multi-functional approach allows the same CAR-T cell product to effectively target both rapidly proliferating tumor cells and slow-cycling cancer stem cells, achieving both high killing rate and broad adaptability
Data Source
AI summary
The disclosure provides therapeutic combinations of chimeric antigen receptor T cells that specifically bind human STEAP2 (e.g., AZD0754) with androgen receptor antagonists (e.g., enzalutamide). Methods of administering the combinations to treat cancer (e.g., prostate cancer) are also provided.